WEST PHARMACEUTICAL SERVICES INC
West Pharmaceutical Services designs and manufactures containment and delivery systems for injectable drugs and healthcare products, serving biologic, generic, pharmaceutical, diagnostic and medical device companies. Its Proprietary Products segment offers packaging components such as stoppers, seals, syringe and cartridge components, along with vials, syringes, plungers, cartridges, self-injection devices, integrated systems and analytical lab services. It also provides engineering, regulatory and technical support. The Contract-Manufactured Products segment designs, manufactures and assembles complex components and devices for pharmaceutical, diagnostic and medical device customers, as well as consumer products. West makes money by selling proprietary products and services and by providing custom contract-manufacturing and assembly solutions. Its products and services are sold primarily through its own sales force and distribution network, with limited use of contract sales agents and regional distributors. The company has manufacturing facilities in North and South America, Europe and Asia, and is headquartered in Exton, Pennsylvania.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $WST in the last 30 days.
See all $WST insider activity →Jefferies raised its price target for West Pharmaceutical Services (WST) to $475 from $410, citing growth in high-value products and GLP-1 components. The stock has surged 50% year-to-date. WST reported Q3 2026 earnings of $2.66 per share on revenue of $874.5 million, beating estimates, and raised its full-year outlook.
Citigroup kept its Buy rating on West Pharmaceutical Services and raised its price target to $494 from $412, suggesting a 19.7% upside from the Oct 30 close. Recent analyst targets range from $480 to $500.
TD Cowen reaffirmed its Buy rating for West Pharmaceutical Services and increased its price target to $500 from $420, citing a 21.2% potential upside from the last close of $412.62. Recent analyst notes on the company have price targets ranging from $420 to $500.
Over the past 7 days, AlphAI's AI scored 19 news stories mentioning WST (WEST PHARMACEUTICAL SERVICES INC). Coverage has skewed bullish: 17 bullish, 2 neutral, and 0 bearish.
Recent WST coverage spans financial news, corporate actions and earnings.
Analyst upgrade with higher price target suggests upside potential.
Analyst upgrade may lift the stock as investors price in higher valuation.
Analyst upgrade suggests upside potential.
Street PT uplift is a bullish signal, but the article is only an analyst note update with no new company fundamentals.
Target raise suggests potential upside for the stock.
AlphAI scores every news story that mentions WST with an AI model for sentiment and relevance, and aggregates insider trades from WEST PHARMACEUTICAL SERVICES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Jefferies raised its price target for West Pharmaceutical Services (WST) to $475 from $410, citing growth in high-value products and GLP-1 components. The stock has surged 50% year-to-date. WST reported Q3 2026 earnings of $2.66 per share on revenue of $874.5 million, beating estimates, and raised its full-year outlook.
2 min readCitigroup kept its Buy rating on West Pharmaceutical Services and raised its price target to $494 from $412, suggesting a 19.7% upside from the Oct 30 close. Recent analyst targets range from $480 to $500.
1 min readTD Cowen reaffirmed its Buy rating for West Pharmaceutical Services and increased its price target to $500 from $420, citing a 21.2% potential upside from the last close of $412.62. Recent analyst notes on the company have price targets ranging from $420 to $500.
1 min readBarclays raised its price target for West Pharmaceutical Services to $500, up from $440, while maintaining an Overweight rating. The new target suggests a 20% upside from the Oct 29 close of $416.67. Recent analyst price targets for the company range from $420 to $480.
1 min readEvercore ISI Group raised its price target for West Pharmaceutical Services to $480 from $440, maintaining an Outperform rating. This implies a 15.2% upside from the Oct 29 close of $416.67.
1 min readWest Pharmaceutical Services (WST) reported Q3 2026 net sales of $874.5M, up 8.7%, and adjusted EPS of $2.66, up 35.7%. The company raised full-year guidance for net sales to $3.41B-$3.42B and adjusted EPS to $9.38-$9.48. Q3 saw strong growth in HVP Components and share buybacks of $231M.
2 min readWest Pharmaceutical Services secured $950M in new credit facilities, including a $750M revolving line and a $200M term loan, to refinance existing debt and support liquidity. The company repaid $130M under its prior agreement, which was terminated without penalties.
1 min readWEST PHARMACEUTICAL SERVICES INC (WST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into a Material Definitive Agreement. The information contained in Item 2.03 below is incorporated herein by reference. Item 1.02 Termination of a Material Definitive Agreement. 2019 Credit Agreement On October 26, 2026 (the “Effective Date”), West Pharmaceutical
2 min readWest Pharmaceutical Services (NYSE: WST) declared a $0.26 per share quarterly dividend, an 18% increase from the prior quarter. This marks the 34th consecutive annual dividend increase. The dividend is payable on November 18, 2026, to shareholders of record on November 11, 2026. The company reported $3.07 billion in net sales for fiscal year 2025.
2 min readWest Pharmaceutical Services, Inc. raised its dividend for 34 consecutive years, with the next payment being $0.26 per share. The company is a leading provider of injectable solutions and services, with global operations and over 10,000 employees. It generated significant revenue in fiscal year 2025, according to the company.
1 min read
